CTOs on the Move


 
Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ludesi.com
  • 1 Amherst St
    Cambridge, MA USA 02142
  • Phone: 617.297.2810

Executives

Name Title Contact Details

Similar Companies

Creative Biogene.Inc

Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plenum Scientific Research

Plenum Scientific Research, Inc is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beyond Air

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.

Molecular Therapeutics

Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.